Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma

被引：2

作者：

Bukhari, Nedal ^{[1
,2
]}

Abdalla, Khalda ^{[1
]}

Ibnshamsa, Fahad ^{[1
]}

Alselwi, Waleed ^{[1
]}

Al-Shakir, Shakir ^{[3
]}

Alqahtani, Mohammed ^{[4
]}

机构：

[1] King Fahad Specialist Hosp, Dept Med Oncol, Dammam, Saudi Arabia

[2] Imam Abdulrahman Bin Faisal Univ, Dept Internal Med, Dammam, Saudi Arabia

[3] King Fahad Specialist Hosp, Dept Radiat Oncol, Dammam, Saudi Arabia

[4] King Fahad Specialist Hosp, Multiorgan Transplant Ctr, Dammam, Saudi Arabia

来源：

CUREUS JOURNAL OF MEDICAL SCIENCE | 2021年 / 13卷 / 10期

关键词：

chemotherapy; nab-paclitaxel; gemcitabine; folfirinox; pancreatic cancer; CANCER; FOLFIRINOX; SURVIVAL;

D O I：

10.7759/cureus.18756

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Pancreatic cancer is an extremely lethal malignancy with the majority of patients presenting with advanced disease. Typically, fit patients with advanced unresectable disease are treated with chemotherapy, which comprises either first-line folfirinox (FNX) or gemcitabine/nab-paclitaxel (GNP) regimens based on level 1 evidence. To our knowledge, robust evidence for second-line GNP post FNX does not exist. We herein report four cases treated at our institute with second-line GNP. Amongst those were patients with durable responses lasting over a year, which is extremely rare in stage 4 pancreatic cancer.

引用

页数：9

共 23 条

[1] Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial [J].

Aung, Kyaw L. ;

Fischer, Sandra E. ;

Denroche, Robert E. ;

Jang, Gun-Ho ;

Dodd, Anna ;

Creighton, Sean ;

Southwood, Bernadette ;

Liang, Sheng-Ben ;

Chadwick, Dianne ;

Zhang, Amy ;

O'Kane, Grainne M. ;

Albaba, Hamzeh ;

Moura, Shari ;

Grant, Robert C. ;

Miller, Jessica K. ;

Mbabaali, Faridah ;

Pasternack, Danielle ;

Lungu, Ilinca M. ;

Bartlett, John M. S. ;

Ghai, Sangeet ;

Lemire, Mathieu ;

Holter, Spring ;

Connor, Ashton A. ;

Moffitt, Richard A. ;

Yeh, Jen Jen ;

Timms, Lee ;

Krzyzanowski, Paul M. ;

Dhani, Neesha ;

Hedley, David ;

Notta, Faiyaz ;

Wilson, Julie M. ;

Moore, Malcolm J. ;

Gallinger, Steven ;

Knox, Jennifer J. .

CLINICAL CANCER RESEARCH, 2018, 24 (06) :1344-1354

[2] Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals [J].

Azam, Faisal ;

Latif, Muhammad Farooq ;

Farooq, Ayesha ;

Tirmazy, Syed Hammad ;

AlShahrani, Saad ;

Bashir, Shahid ;

Bukhari, Nedal .

CASE REPORTS IN ONCOLOGY, 2019, 12 (03) :728-736

[3]

Bukhari N, 2017, CASE REP ONCOL, V10, P577, DOI 10.1159/000477841

[4] Early Stage Anaplastic Sarcomatoid Carcinoma of The Pancreas, A Case Report [J].

Bukhari, Nedat ;

Joudeh, Amani .

AMERICAN JOURNAL OF CASE REPORTS, 2019, 20 :597-601

[5] Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis [J].

Chae, Heejung ;

Jeong, Hyehyun ;

Cheon, Jaekyung ;

Chon, Hong Jae ;

Ryu, Hyewon ;

Kim, Il-Hwan ;

Kang, Myoung Joo ;

Jeong, Jae Ho ;

Ryoo, Baek-Yeol ;

Kim, Kyu-pyo ;

Yoo, Changhoon .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12

[6] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].

Conroy, Thierry ;

Desseigne, Francoise ;

Ychou, Marc ;

Bouche, Olivier ;

Guimbaud, Rosine ;

Becouarn, Yves ;

Adenis, Antoine ;

Raoul, Jean-Luc ;

Gourgou-Bourgade, Sophie ;

de la Fouchardiere, Christelle ;

Bennouna, Jaafar ;

Bachet, Jean-Baptiste ;

Khemissa-Akouz, Faiza ;

Pere-Verge, Denis ;

Delbaldo, Catherine ;

Assenat, Eric ;

Chauffert, Bruno ;

Michel, Pierre ;

Montoto-Grillot, Christine ;

Ducreux, Michel .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825

[7] Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children [J].

Drilon, A. ;

Laetsch, T. W. ;

Kummar, S. ;

DuBois, S. G. ;

Lassen, U. N. ;

Demetri, G. D. ;

Nathenson, M. ;

Doebele, R. C. ;

Farago, A. F. ;

Pappo, A. S. ;

Turpin, B. ;

Dowlati, A. ;

Brose, M. S. ;

Mascarenhas, L. ;

Federman, N. ;

Berlin, J. ;

El-Deiry, W. S. ;

Baik, C. ;

Deeken, J. ;

Boni, V. ;

Nagasubramanian, R. ;

Taylor, M. ;

Rudzinski, E. R. ;

Meric-Bernstam, F. ;

Sohal, D. P. S. ;

Ma, P. C. ;

Raez, L. E. ;

Hechtman, J. F. ;

Benayed, R. ;

Ladanyi, M. ;

Tuch, B. B. ;

Ebata, K. ;

Cruickshank, S. ;

Ku, N. C. ;

Cox, M. C. ;

Hawkins, D. S. ;

Hong, D. S. ;

Hyman, D. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (08) :731-739

[8]

Dumont R, 2017, Acta Gastroenterol Belg, V80, P451

[9] Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer [J].

Golan, Talia ;

Hammel, Pascal ;

Reni, Michele ;

Van Cutsem, Eric ;

Macarulla, Teresa ;

Hall, Michael J. ;

Park, Joon-Oh ;

Hochhauser, Daniel ;

Arnold, Dirk ;

Oh, Do-Youn ;

Reinacher-Schick, Anke ;

Tortora, Giampaolo ;

Alguel, Hana ;

O'Reilly, Eileen M. ;

McGuinness, David ;

Cui, Karen Y. ;

Schlienger, Katia ;

Locker, Gershon Y. ;

Kindler, Hedy L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04) :317-327

[10] Pancreatic cancer [J].

Kamisawa, Terumi ;

Wood, Laura D. ;

Itoi, Takao ;

Takaori, Kyoichi .

LANCET, 2016, 388 (10039) :73-85

← 1 2 3 →